Thin Film Electronics ASA – Reminder of last day of the subscription period in the Subsequent Offering
Oslo, 29 June 2020
Day: June 29, 2020
Rybelsus® approved in Japan for the treatment of type 2 diabetes
Written by Customer Service on . Posted in Public Companies.
Bagsværd, Denmark, 29 June 2020 – Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus® (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes.The approval of Rybelsus® in Japan is based on results from the PIONEER clinical trial programme, which involved more than 9,500 adults with type 2 diabetes, including approximately 1,300 adults from Japan. The approved label reflects the Japanese studies, which showed that Rybelsus® 7 mg once daily was comparable to liraglutide 0.9 mg once daily and, in combination with one other oral antidiabetic treatment, Rybelsus® 7 mg once daily was comparable to dulaglutide 0.75 mg once weekly, while Rybelsus® 14 mg once daily resulted in significantly...
Finanskalender 2020/21
Written by Customer Service on . Posted in Public Companies.
MEDDELELSE NR. 193 Hermed følger offentliggørelsesdatoer for ChemoMetecs planlagte meddelelser, herunder også datoer for generalforsamlinger i 2020 og 2021:17. september 2020 – Årsrapport (2019/20)8. oktober 2020 – Ordinær generalforsamling5. november 2020 – Periodemeddelelse (1. kvartal 2020/21)5. februar 2021 – Halvårsrapport (2020/21)6. maj 2021 – Periodemeddelelse (3. kvartal 2020/21)16. september 2021 – Årsrapport (2020/21)7. oktober 2021 – Ordinær generalforsamlingEventuelle henvendelser:Om ChemoMetec A/SChemoMetec udvikler, producerer og markedsfører analyseinstrumenter til celletælling og en lang række andre målinger. ChemoMetecs analyseinstrumenter markedsføres globalt inden for blandt andet pharma, biotek og landbrug. ChemoMetec har nogle af verdens førende...
Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China
Written by Customer Service on . Posted in Public Companies.
SHANGHAI, China, June 28, 2020 (GLOBE NEWSWIRE) — On June 29, 2020, Burning Rock Biotech Limited (NASDAQ: BNR) announced a strategic partnership with CStone Pharmaceuticals (HKEX: 2616) to co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients.“In an era of rapid development of precision medicines, CDx is of great significance to accurately identify the patient populations who could benefit from specific therapies. Burning Rock will continue to develop CDx-related products based on advanced next generation sequencing (NGS) technology, and work with partners to promote the clinical application of precision diagnostics and treatment, potentially bringing clinical benefits...
